Amisha Vora of Prabhudas Lilladher told CNBC-TV18, "Currently within the pharma pack out top pick is Glenmark Pharma. We think that Glenmark has almost more than 35-40 products which is more than 36 months older where US permissions are likely to come soon. They also have some in licensing opportunities over next 12-24 months. We think that they should be in a position to generate more than probably Rs 2,000 crore of cash to retire a good amount of debt. That continuous to be our top pick."
"Sun Pharma being one of the very well stock coming after a very long time in terms of some of the US related issues into troubles on one of their plants, I don’t think in a hurry it is going to bounce back. May be if over couple of quarters things don’t turn around some positions can get paired so I am not in a very much hurry at the moment," he said.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
